================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------
FORM 8-K
---------------------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): January 14, 2002
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-28150 33-0525145
(STATE OR OTHER JURISDICTION (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER
OF INCORPORATION) IDENTIFICATION NO.)
10555 SCIENCE CENTER DRIVE, SAN DIEGO, CA 92121
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (858) 658-7600
N/A
(Former name or former address, if changed since last
report.)
================================================================================
This Current Report on Form 8-K is filed by Neurocrine Biosciences, Inc., a
Delaware corporation (the "Company"), in connection with the matters described
herein.
ITEM 5. OTHER EVENTS
On January 11, 2002, the Company announced that its Board of Directors
approved an amendment of its shareholder rights plan to increase the initial
exercise price of the rights issued pursuant to the plan from $51.75 to $350.00
per right.
The intent of the increase is to preserve the effectiveness of the plan in
view of the recent appreciation of the company's stock price. No other
amendments were made to the plan. The shareholder rights plan was originally
approved in April 1997. The Company was advised by Robertson Stephens, Inc.
ITEM 7. EXHIBITS
(a) Exhibits. The following exhibits are filed herewith:
Exhibit
Number Description of Exhibit
------ ----------------------
4.1 Amended and Restated Preferred Shares Rights Agreement
99.1 Press Release dated January 11, 2002
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: January 14, 2002 NEUROCRINE BIOSCIENCES, Inc.
By: /s/ PAUL W. HAWRAN
-----------------------------------
Paul W. Hawran
Executive Vice President and
Chief Financial Officer